Eksponeringen for nilotinib hos raske forsøgspersoner 3- dobledes ved samtidig administration med den stærke CYP3A4- hæmmer ketoconazol.
The exposure to nilotinib in healthy subjects was increased 3-fold when co-administered with the strong CYP3A4 inhibitor ketoconazole.